53 publications
Name | Date | Type | Actions |
---|---|---|---|
2020 annual results 2020 sales: €427.5m (up 8.0% as reported)
EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m
|
Public releases | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - February 2021 As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » |
Voting rights | ||
Programme de rachat - February 2021 Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres |
Monthly communication regarding buyback programs | ||
Vetoquinol wins the Animal Pharm’s award for best European company 2020 February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm. |
Public releases | ||
Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health. |
press release excluding results | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - January 2021 |
Voting rights | ||
Programme de rachat - January 2021 Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres |
Monthly communication regarding buyback programs | ||
2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate) Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.” |
Public releases | ||
Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements. |
Public releases | ||
Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health. |
Public releases |